MicroBio is a clinical stage company dedicated to developing therapies to “rebalance the immune system” in patients with autoimmune diseases, when a person’s immune system attacks the body’s own tissues. Led by Professor Simon Davies and Professor Richard Kornal, the company spun off from the University of Oxford in 2019 and raised $130 million in venture capital funding, including a $97 million tranche back in June from a host of backers including Oxford Science Enterprises (operating environment), an investment firm that has backed more than 100 Oxford University subsidiaries since its founding in 2015.
The University of Oxford and the nearby University of Cambridge have long been hotbeds for both venture capital and M&A. Back in 2014 Google bought DeepMind, an AI-focused subsidiary of the University of Cambridgewhich in turn hired two AI teams from Oxford later that year.
More recently, Meltwater acquired another Oxford University subsidiary called DeepReason.AI. $7.3 million deal back in November.
Originally founded as Oligogen back in 1987, Gilead develops antivirals used to treat hepatitis B, HIV/AIDS, influenza and, most recently, Covid-19. company this week increased sales forecast amid expected demand for the Covid-19 drug Veklury, which received FDA approval earlier this year.
Taking MicroBio into its own hands, this will serve Gilead with MicroBio’s patented technology and “portfolio of immune inhibitory receptor agonists,” according to to the statement.
Credit: techcrunch.com /